Head & Neck/Thyroid Cancers
Conference Coverage
AML risk is doubled in low-risk thyroid cancer patients unnecessarily given radioactive iodine therapy
MADRID - Unnecessary radioactive iodine treatment is associated with nearly twice the risk of developing acute myeloid leukemia (AML) in patients...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
Conference Coverage
Big changes coming for thyroid cancer staging
How big an impact will new thyroid staging criteria have on the numbers of stage I disease? It’ll be huge.
Conference Coverage
Contralateral nodal thyroid metastases show slow progression
BOSTON – In some thyroid cancers, a small level III contralateral nodal metastasis may be watched safely rather than resected.
Conference Coverage
Revised thyroid Bethesda System resets malignant risks
BOSTON – Revised thyroid cancer cytology system “limits malignancy to cases with features of classic malignant papillary thyroid carcinoma.”
Conference Coverage
VIDEO: Lenvatinib’s real-world thyroid cancer performance matches trial
The median time of progression-free survival was 10 months in the registry and 18 months in the pivotal trial.
Conference Coverage
Thyroid-nodule size boosts serum thyroglobulin’s diagnostic value
Size does matter – at least when it comes to normalizing the serum thyroglobulin level.
Conference Coverage
VIDEO: Less follow-up proposed for low-risk thyroid cancer
BOSTON – Can some patients with good treatment responses safely transition to follow-up monitoring at longer intervals?
How We Do It
Prehabilitation for lymphedema in head and neck cancer patients at a community cancer center
Conference Coverage
VIDEO: Routine genomic testing identifies actionable alterations in 52% of tumors
CHICAGO – A trend was observed in longer overall survival among those patients who received recommended treatments.
Conference Coverage
Oral HPV infections sharply lower for vaccinated youth
HPV vaccination appears to confer a high level of protection against oral infection with oncogenic virus types.